Daniel Omstead, Ph.D., is President and CEO of Tekla Capital Management and President of H&Q Lifesciences Investors and H&Q Healthcare Investors; two NYSE listed closed-end mutual funds that make venture and public equity investments in small, emerging healthcare-related companies. Previously, he was President and CEO of Reprogenesis, Inc. a private development stage biotech regenerative medicine company, which merged with two other companies to form Curis, Inc., and was Senior Vice President, R&D at Cytotherapeutics, Inc., a public biotech company in CNS therapies. He holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Rajeev joined SR One in 2003 and serves as a director on the boards of IlluminOss Medical and Synovex. He is involved with SR Ones investments in Cydex, Hypnion, Predix Pharmaceuticals, Rib-X Pharmaceuticals, Octoplus, Trigen, Nucleonics, and Pinnacle Pharmaceuticals. He was at the Competitive Excellence Group within GSK working on company-wide strategic projects and also worked at Genentech, in technology and clinical development, and product development. He was a co-founder of Unimicro Technologies, a biomedical analysis company. He received his B.A. in Chemistry and Mathematics from Knox College, an M.B.A. from the Wharton School of the University of Pennsylvania, and his Ph.D. in Chemistry from Stanford University.
Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a General Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm’s North American operations. Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practice. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich. Fouad’s academic credentials include a Master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained an MBA in Finance & Strategy from the University at Buffalo in New York.
Ms. Martha Shadan joined Rotation Medical in 2013, bringing more than three decades of marketing and commercialization expertise to her role as CEO. Shadan joined Rotation Medical in 2013, bringing more than three decades of marketing and commercialization expertise to her role as CEO. She has held senior executive positions in leading medical device companies, including President of the Trauma Division at Zimmer, Vice President/General Manager of Vascular Therapies and Vice President/General Manager of Biosurgery and Sports Surgery at Covidien, and senior roles at Bristol Myers Squibb and EMD Millipore. Shadan earned her M.B.A. from Northeastern University, M.S. in biology from Michigan State University and a B.S. in biology from the University of New Hampshire. She is a member of AdvaMed, sitting on the board of directors for the organization as well as its Accel division, and she is part of the leadership circle for its Women’s Executive Network (WEN).
Mr. Jeff Bailey most recently served as Chairman and CEO of Neurovance, and brings over 30 years of leadership experience across various functional areas including supply chain, commercial, finance, R&D and business development. In Q1 of 2017 he led Neurovance’s acquisition by Otsuka. Previously, he has held positions as President and CEO of Lantheus Medical Imaging Inc., leading the company to a successful IPO. He also served as COO of Fougera Pharmaceuticals (acquired by Novartis), Chief Commercial Officer for King Pharmaceuticals (acquired by Pfizer), and held earlier executive positions at Novartis Pharmaceuticals as president of an operating unit. He was with Johnson and Johnson (including Janssen Pharmaceuticals) for 22 years. Bailey earned a business degree from Rutgers University. He also served on the board of Landauer, Inc. (NYSE – LDR) through its acquisition by Fortive in September 2017.